**In Silico ADMET Predictions: Enhancing Drug Development through QSAR Modeling**

**1Suvidhi, 2\*Sudesh Kumar**

1Senior Research Fellow, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001

2Senior Research Fellow, National Centre for Veterinary Type Cultures, ICAR-NRCE, Hisar, Haryana, 125001

\*Corresponding author Email: sudeshdedar@gmail.com

**Abstract**

 In the realm of drug development, accurate prediction of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties for potential compounds is of paramount importance to identify promising lead candidates at an early stage. In Silico ADMET predictions, driven by the prowess of Quantitative Structure-Activity Relationship (QSAR) models, have emerged as indispensable tools, streamlining the drug discovery pipeline. This article delves into the application of QSAR modeling in ADMET predictions, emphasizing its critical role in prioritizing and fine-tuning lead compounds with enhanced pharmacokinetic and safety profiles. Through the integration of computational techniques, QSAR modeling enables drug developers to make informed decisions, accelerating the identification of safer and more effective therapeutic candidates.

**Introduction**

 The discovery and development of novel drugs to combat complex diseases and medical conditions have long been an arduous journey for pharmaceutical researchers. The multifaceted challenges of identifying effective compounds with optimal pharmacokinetic properties and minimal toxicity have often resulted in high attrition rates and substantial financial investments. In response to these challenges, scientists have sought innovative approaches to expedite and enhance the drug development process.

 Accurate assessment of a drug candidate's Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties plays a pivotal role in identifying potential lead compounds and evaluating their suitability for further development. ADMET evaluation provides critical insights into a compound's bioavailability, systemic exposure, potential interactions with metabolic pathways, and its likelihood of causing adverse effects. Traditionally, the determination of ADMET properties relied heavily on laborious and time-consuming experimental studies, contributing to the extended drug development timelines.

 In recent years, In Silico ADMET predictions have emerged as a promising and cost-effective strategy to overcome these challenges. Leveraging the power of computational tools, particularly Quantitative Structure-Activity Relationship (QSAR) models, researchers can now predict ADMET properties early in the drug design process. This enables the rapid screening of large chemical libraries, allowing for the identification of lead compounds with favorable pharmacokinetic and safety profiles, while minimizing the need for extensive experimental testing.

 The integration of QSAR models in ADMET predictions represents a paradigm shift in the drug discovery landscape. By exploiting the relationship between a compound's chemical structure and its biological activity, QSAR models offer a systematic and efficient approach to quantitatively relate molecular properties to ADMET outcomes. Through the utilization of diverse molecular descriptors and advanced machine learning algorithms, these models can capture complex interactions and patterns, generating reliable predictions for a wide range of ADMET parameters.

 In this article, we explore the application of QSAR modeling in the context of In Silico ADMET predictions, emphasizing its significance in streamlining drug discovery and optimization processes. We delve into the principles and methodologies of QSAR modeling and discuss its integration with ADMET prediction, highlighting its potential to revolutionize the early stages of drug development. Furthermore, we review recent advancements in computational techniques and data availability that have augmented the predictive accuracy and utility of QSAR models in ADMET evaluations.

 Through a comprehensive analysis of current research and case studies, we aim to provide a comprehensive understanding of how In Silico ADMET predictions are transforming drug discovery. Moreover, we discuss how these predictive models contribute to the rational design of compounds, enabling medicinal chemists to focus on promising candidates with enhanced therapeutic potential and reduced safety risks. Ultimately, the adoption of In Silico ADMET predictions through QSAR modeling holds the promise of accelerating drug development timelines, reducing costs, and increasing the success rate of bringing new and improved medications to the market.

**QSAR Modeling in ADMET Predictions**

 Quantitative Structure-Activity Relationship (QSAR) modeling is a computational technique that establishes a quantitative correlation between the chemical structure of molecules and their biological activity or properties. In the context of drug development, QSAR models have been successfully applied to predict ADMET properties, enabling researchers to prioritize lead compounds and assess their pharmacokinetic and safety profiles early in the drug discovery process.

1. **Molecular Descriptors in QSAR Modeling:** At the heart of QSAR modeling are molecular descriptors, which are numerical representations of chemical structures. These descriptors encode various physicochemical, electronic, and geometric properties of molecules, capturing essential features that influence their interactions with biological targets and physiological systems. Common molecular descriptors include 2D descriptors (e.g., molecular weight, logP, and hydrogen bond donors/acceptors) and 3D descriptors (e.g., molecular surface area, volume, and shape).
2. **Selection of Relevant Descriptors for ADMET Predictions:** Given the complexity of ADMET properties, it is crucial to carefully choose molecular descriptors that are relevant to the specific ADMET parameters of interest. For example, when predicting drug absorption, descriptors related to lipophilicity and polarity may be crucial, whereas for toxicity predictions, descriptors related to chemical reactivity and metabolic stability are essential.
3. **Statistical Methods in QSAR Modeling:** QSAR models are built on statistical methods that quantify the relationship between molecular descriptors and ADMET properties. One common approach is multiple linear regression, where the model aims to find the best-fit linear equation relating the descriptors to the target property. Other regression techniques, such as partial least squares (PLS) regression and support vector regression (SVR), are also widely used to handle large and complex datasets.
4. **Machine Learning Algorithms in QSAR Modeling:** In recent years, the application of machine learning algorithms has significantly advanced QSAR modeling capabilities. Supervised machine learning techniques, such as random forests, decision trees, and neural networks, can capture nonlinear relationships between descriptors and ADMET properties, allowing for more accurate predictions. Additionally, ensemble methods, which combine multiple models, often lead to improved predictive performance and robustness.
5. **Data Collection and Model Validation:** The success of QSAR models in predicting ADMET properties heavily relies on high-quality, diverse, and well-curated datasets. Adequate representation of various chemical classes and ADMET outcomes is essential to develop robust models with broad applicability. Model validation techniques, such as cross-validation and external validation, are employed to assess the predictive performance and generalization ability of QSAR models.
6. **Interpretability and Applicability Domain:** Interpreting QSAR models is crucial for gaining insights into the factors influencing ADMET properties. By analyzing the model coefficients or feature importance scores, researchers can identify key molecular attributes responsible for specific ADMET outcomes. Additionally, defining the applicability domain of QSAR models ensures that predictions are reliable and relevant for chemical structures within the model's training space.

 QSAR modeling represents a powerful approach in predicting ADMET properties of potential drug candidates. Through the selection of relevant molecular descriptors, the implementation of appropriate statistical methods, and the integration of machine learning algorithms, QSAR models can provide valuable insights into the pharmacokinetic and safety profiles of compounds early in the drug discovery process. By enabling rapid and cost-effective screening of chemical libraries, QSAR-based ADMET predictions play a crucial role in guiding medicinal chemists towards the selection and optimization of lead compounds with improved chances of success in drug development.

**Predicting Absorption**

 The process of drug absorption involves the passage of a drug molecule from its site of administration into the systemic circulation, where it can exert its pharmacological effect. Understanding the absorption characteristics of potential drug candidates is critical for assessing their bioavailability and efficacy. In the context of drug discovery, QSAR models have emerged as valuable tools to predict various aspects of drug absorption, such as oral absorption and intestinal permeability, aiding in the early selection and optimization of lead compounds.

1. **Oral Absorption Prediction:** Oral administration is one of the most common routes of drug delivery due to its convenience and patient compliance. However, the oral bioavailability of a drug is influenced by several factors, including its physicochemical properties, solubility, and permeability across gastrointestinal barriers. QSAR models are used to establish quantitative relationships between molecular descriptors and oral bioavailability, allowing researchers to predict the fraction of an orally administered drug that reaches the systemic circulation.
2. **Intestinal Permeability Prediction:** Intestinal permeability refers to the ability of a drug to traverse the intestinal epithelial barrier and enter the bloodstream. It is a critical determinant of oral absorption and can greatly impact the bioavailability of a drug. QSAR models leverage molecular descriptors related to lipophilicity, molecular size, and hydrogen bonding capacity to predict the permeability of drugs across the intestinal membrane.
3. **Solubility Prediction:** Drug solubility is another crucial factor influencing absorption. Poorly water-soluble drugs may face challenges in dissolving and being absorbed through the gastrointestinal tract. QSAR models can estimate drug solubility based on molecular descriptors related to hydrophobicity, polarity, and other physicochemical properties, providing insights into potential solubility issues that might affect oral bioavailability.
4. **Blood-Brain Barrier (BBB) Permeability:** For drugs intended to target the central nervous system (CNS), crossing the blood-brain barrier is essential. QSAR models can be applied to predict the permeability of drugs across the BBB, helping researchers identify candidates with the potential to reach therapeutic concentrations in the brain.
5. **Predicting Efflux Transporter Interactions:** Efflux transporters, such as P-glycoprotein (P-gp), play a significant role in drug absorption by actively pumping drugs out of intestinal cells, limiting their bioavailability. QSAR models can aid in predicting the likelihood of a drug being a substrate for efflux transporters, providing insights into potential interactions and their impact on oral absorption.
6. **High-Throughput Screening:** With advancements in automation and data handling, QSAR models are increasingly being integrated into high-throughput screening platforms. This enables the rapid prediction of absorption-related properties for large chemical libraries, expediting the identification of potential lead compounds for further development.

 In summary, predicting drug absorption is a crucial step in early drug development. QSAR models offer a powerful approach to estimating oral absorption, intestinal permeability, and other relevant parameters based on molecular descriptors and statistical relationships. By providing insights into a compound's bioavailability and potential challenges related to absorption, QSAR-based predictions assist researchers in selecting and optimizing lead compounds with improved oral bioavailability and pharmacokinetic profiles, ultimately contributing to the success of the drug development process.

**Distribution and Metabolism Predictions**

 Understanding how drugs are distributed and metabolized within the body is crucial for optimizing their pharmacokinetic properties and therapeutic efficacy. The distribution of drugs across various tissues and their interactions with transporters and metabolizing enzymes play a significant role in determining drug concentration profiles and potential drug-drug interactions. In this context, QSAR models have proven to be valuable tools for predicting distribution and metabolism-related parameters, offering insights into plasma protein binding, tissue distribution, and metabolic stability.

1. **Plasma Protein Binding Prediction:** Plasma protein binding refers to the extent to which a drug binds to proteins in the blood, primarily albumin and alpha-1 acid glycoprotein. Bound drugs are generally unavailable for distribution and elimination, impacting their free, active fraction. QSAR models can predict the percentage of drug bound to plasma proteins based on molecular descriptors related to drug-protein interactions and physicochemical properties.
2. **Tissue Distribution Prediction:** The distribution of drugs into various tissues depends on factors such as tissue perfusion, drug lipophilicity, and the presence of specific transporters. QSAR models can provide insights into tissue-specific drug distribution by relating molecular descriptors to tissue affinity and permeation characteristics. These predictions aid in understanding a drug's potential to accumulate in target tissues and may contribute to dose optimization and therapeutic targeting.
3. **Interaction with Transporters:** Membrane transporters, such as P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATPs), influence the distribution of drugs across biological barriers. QSAR models can be utilized to predict a drug's interaction with these transporters, enabling researchers to assess the likelihood of efflux or uptake by transporters and their impact on drug distribution.
4. **Metabolic Stability Prediction:** Metabolism plays a critical role in drug elimination and clearance. Metabolic stability is a measure of how resistant a drug is to metabolism by enzymes, such as cytochrome P450s (CYPs) and other phase I and phase II enzymes. QSAR models can estimate a drug's metabolic stability based on its chemical structure and molecular descriptors. Predictions in this area help researchers identify potential drug candidates that are less prone to rapid metabolism, leading to longer half-lives and extended therapeutic effects.
5. **Drug-Drug Interaction Predictions:** QSAR models have also been employed to predict potential drug-drug interactions arising from competition for transporters or metabolism enzymes. By evaluating the interactions between drugs and relevant molecular targets, researchers can anticipate the likelihood of drug interactions and make informed decisions during drug development and prescribing practices.
6. **Application in Lead Optimization:** Distribution and metabolism predictions through QSAR models significantly impact lead optimization efforts. By identifying compounds with favorable distribution profiles, low plasma protein binding, and desirable metabolic stability, researchers can prioritize lead candidates with optimal pharmacokinetic characteristics, reducing the risk of adverse effects and enhancing therapeutic efficacy.

 QSAR modeling offers a valuable approach to estimate distribution and metabolism-related parameters, aiding in the early identification and optimization of lead compounds with improved pharmacokinetic profiles. By leveraging molecular descriptors and statistical relationships, researchers can gain insights into plasma protein binding, tissue distribution, metabolic stability, and potential drug-drug interactions, facilitating rational decision-making during drug development and optimizing therapeutic outcomes.

**Excretion and Toxicity Predictions**

 Efficient excretion and mitigation of potential toxic effects are essential aspects of drug design and development. Predicting a drug's clearance from the body, particularly through renal and hepatic pathways, is crucial for understanding its elimination kinetics and ensuring appropriate dosing regimens. Additionally, assessing potential toxicity issues, such as liver and cardiac toxicities, is paramount for enhancing drug safety. In this section, we explore how QSAR models have been employed to predict excretion parameters and toxicity risks, offering valuable insights for rational drug design and optimization.

1. **Renal Clearance Prediction:** Renal clearance represents the rate at which a drug is eliminated from the body through the kidneys. QSAR models utilize molecular descriptors related to the physicochemical properties of drugs, their affinity for renal transporters, and filtration characteristics to predict renal clearance. Accurate predictions of renal clearance facilitate dosing regimen optimization and can be crucial in cases where renal function may be compromised, such as in patients with renal impairment.
2. **Hepatic Clearance Prediction:** Hepatic clearance is the primary pathway for the metabolism and elimination of many drugs. QSAR models are employed to estimate hepatic clearance by considering factors such as a drug's affinity for hepatic enzymes (e.g., cytochrome P450s) and potential interactions with hepatic transporters. Accurate predictions of hepatic clearance aid in understanding a drug's metabolic fate and potential interactions with other drugs that undergo hepatic metabolism.
3. **Toxicity Predictions:** Assessing drug toxicity is a critical step in drug development to ensure patient safety. QSAR models have been utilized to predict the potential toxic effects of drugs, including liver and cardiac toxicities. By integrating molecular descriptors associated with toxicity endpoints, such as chemical reactivity and structural alerts, QSAR models can identify compounds with a higher likelihood of inducing adverse effects.
4. **Liver Toxicity Prediction:** Drug-induced liver toxicity is a significant concern in drug development. QSAR models can predict the hepatotoxic potential of drug candidates by incorporating descriptors related to the drug's chemical structure, its potential to form toxic metabolites, and its interaction with liver-specific targets and pathways. Early identification of compounds with a higher risk of liver toxicity can help in selecting safer lead candidates for further development.
5. **Cardiac Toxicity Prediction:** Cardiac toxicity, particularly related to the risk of arrhythmias and cardiotoxicity, is another critical consideration in drug design. QSAR models have been applied to predict the potential cardiotoxicity of drugs by integrating molecular descriptors linked to ion channel interactions, electrochemical properties, and structural features associated with cardiac safety risks.
6. **Structure-Activity Relationship for Toxicity:** QSAR models establish a structure-activity relationship for toxicity by correlating the chemical structure of drugs with their potential toxic effects. Understanding the specific structural features responsible for toxicity allows medicinal chemists to modify drug candidates to mitigate adverse effects while retaining their therapeutic efficacy.

 In conclusion, QSAR modeling plays a significant role in predicting excretion parameters, such as renal and hepatic clearance, and assessing potential toxicity risks, including liver and cardiac toxicities. By leveraging molecular descriptors and statistical relationships, QSAR models provide critical insights for rational drug design, aiding in the selection and optimization of lead compounds with improved safety profiles. Accurate predictions of excretion and toxicity parameters contribute to the development of safer and more effective drugs, ultimately advancing the success of drug development efforts and benefiting patient outcomes.

**Integrating QSAR Predictions in Lead Optimization**

 Lead optimization is a crucial phase in the drug discovery process where potential drug candidates are refined and optimized to improve their pharmacological properties, pharmacokinetic profiles, and safety. QSAR models, by providing early and quantitative predictions of ADMET properties, play a pivotal role in guiding medicinal chemists during lead optimization. By leveraging the insights gained from QSAR predictions, chemists can strategically modify chemical structures to enhance drug-like characteristics, leading to the identification of more promising lead compounds with improved therapeutic potential and reduced risk of adverse effects.

1. **Identifying Favorable Molecular Features:** QSAR models provide medicinal chemists with information on how specific molecular features impact ADMET properties. For example, predictions may reveal that certain substituents increase a drug's oral bioavailability, while others enhance metabolic stability. Armed with this knowledge, chemists can design and synthesize analogs with more favorable molecular features to improve absorption, distribution, metabolism, and excretion characteristics.
2. **Structure-Activity Relationship (SAR) Analysis:** QSAR models establish SARs, which describe the relationship between the chemical structure of a compound and its biological activity or ADMET properties. Through SAR analysis, medicinal chemists can discern the structure-activity relationships responsible for particular ADMET outcomes. By optimizing these structure-activity relationships, they can fine-tune lead compounds, tailoring them to achieve desired ADMET characteristics.
3. **Rapid Compound Prioritization:** In the lead optimization stage, chemists often have a collection of potential lead compounds with diverse chemical structures. QSAR predictions allow for the rapid prioritization of compounds based on their ADMET profiles. Compounds with favorable ADMET properties can be advanced for further evaluation, while those with undesirable properties may be deprioritized, saving time and resources in the drug development process.
4. **Addressing Toxicity Concerns:** By predicting potential toxicity issues early on, QSAR models enable medicinal chemists to identify and modify structural features associated with toxicity risks. This iterative process of structure modification and subsequent QSAR predictions helps in designing safer compounds, reducing the likelihood of adverse effects.
5. **Targeting Specific ADMET Goals:** Depending on the therapeutic target and intended therapeutic application, specific ADMET characteristics may be more desirable. For instance, for CNS drugs, compounds with good blood-brain barrier permeability might be prioritized. QSAR models assist chemists in setting and achieving these ADMET goals during lead optimization.
6. **Reducing Attrition Rates:** By incorporating QSAR predictions into lead optimization, drug developers can address potential ADMET liabilities early in the drug discovery process. This proactive approach helps in reducing high attrition rates in later stages of development, where compounds with unfavorable ADMET properties are more likely to fail.

 In conclusion, the integration of QSAR predictions in lead optimization is a valuable strategy to expedite the identification of promising drug candidates. By guiding medicinal chemists in modifying chemical structures to improve ADMET properties, QSAR models enhance the rational design of lead compounds with better pharmacokinetic and safety profiles. Leveraging the power of computational models and structure-activity relationships, QSAR-based lead optimization holds the promise of accelerating the drug development pipeline and ultimately delivering safer and more effective medications to patients.

**Challenges in In Silico ADMET Predictions**

1. **Data Quality and Availability:** One of the major challenges in developing reliable QSAR models for ADMET predictions is the availability of high-quality and diverse datasets. Limited or biased data can lead to less accurate models, affecting their predictive performance and generalizability.
2. **Complex Interactions:** ADMET processes involve complex interactions between drugs, biological systems, and various transporters and enzymes. Capturing these interactions accurately in QSAR models can be challenging, especially when considering multiple pathways and potential cross-talk between different ADMET parameters.
3. **Interpretability:** As QSAR models become more complex, their interpretability decreases. Understanding the underlying molecular interactions that drive the predictions becomes more challenging, which can hinder the rational design of compounds based on the model's output.
4. **Applicability Domain:** The applicability domain of QSAR models, which defines the chemical space where predictions are reliable, is critical for avoiding extrapolation beyond the model's training data. Defining and validating the applicability domain remains a challenge in ensuring the robustness of QSAR predictions.
5. **Rare Events and Data Imbalance:** Some ADMET outcomes, such as rare toxicities, may have limited occurrences in the available datasets, leading to imbalanced data. Handling imbalanced data is crucial to ensure that the model does not favor the majority class and overlook important minority classes.

**Regulatory Acceptance**

 For In Silico ADMET predictions to be widely accepted and integrated into drug development processes, regulatory agencies must have confidence in the reliability and accuracy of these models. Although progress has been made, there are still challenges to overcome:

1. **Standardization:** The lack of standardized protocols for developing and validating QSAR models for regulatory purposes remains a concern. Consensus guidelines for model development, validation, and reporting would enhance the reproducibility and acceptance of QSAR predictions by regulatory agencies.
2. **Validation with Real-world Data:** Regulatory agencies require models to be validated with external and real-world datasets to demonstrate their robustness and performance in predicting ADMET outcomes for new compounds.

**Future Perspectives and Advancements in QSAR Modeling for ADMET Predictions**

1. Integration of Multi-Omics Data: Incorporating data from various omics disciplines, such as genomics, proteomics, and metabolomics, could enhance the predictive power of QSAR models, capturing a more comprehensive understanding of drug interactions and ADMET properties.
2. Artificial Intelligence and Deep Learning: Advancements in AI and deep learning techniques have the potential to revolutionize QSAR modeling, enabling more accurate predictions by capturing intricate and non-linear relationships between molecular descriptors and ADMET outcomes.
3. Hybrid Approaches: Combining QSAR modeling with other computational methods, such as molecular docking, molecular dynamics simulations, and systems biology, could provide a more comprehensive and integrative approach to predicting ADMET properties.
4. Inclusion of Uncertainty Estimation: Quantifying the uncertainty associated with QSAR predictions would improve the reliability and confidence in the model's results, providing valuable information for decision-making.
5. Collaboration and Data Sharing: Enhanced collaboration between academia, industry, and regulatory agencies, along with data sharing initiatives, can address the challenge of data availability and promote the development of more robust and generalizable QSAR models.

 In Silico ADMET predictions have demonstrated immense potential in expediting drug discovery and optimization processes. However, several challenges related to data quality, model complexity, and regulatory acceptance need to be addressed. Future advancements in QSAR modeling, along with standardization efforts and data sharing initiatives, are expected to pave the way for more reliable and accepted predictive models, ultimately contributing to safer and more effective drug development.

**Conclusions**

 In Silico ADMET predictions, driven by the predictive power of QSAR models, have emerged as indispensable tools in the drug discovery and development landscape. Through the integration of computational methods and molecular descriptors, these predictions offer drug developers valuable insights into the pharmacokinetic and safety profiles of potential lead compounds at an early stage. By leveraging the information obtained from QSAR models, medicinal chemists can strategically design and optimize drug candidates, enhancing their therapeutic potential while minimizing potential adverse effects. The ability to rapidly screen and prioritize lead compounds based on their ADMET properties significantly accelerates the drug discovery process, saving time and resources. QSAR models enable drug developers to make informed decisions on which compounds should be advanced for further evaluation, streamlining the identification of promising candidates for preclinical and clinical studies. Moreover, the integration of In Silico ADMET predictions enhances the safety profile of drug candidates. By predicting potential toxicities and identifying compounds with favorable pharmacokinetic characteristics, researchers can focus their efforts on compounds with a reduced likelihood of causing adverse effects, ultimately leading to safer and more effective therapeutics.

 As computational tools and data availability continue to advance, the reliability and accuracy of QSAR models for ADMET predictions are expected to improve further. By leveraging cutting-edge technologies, such as artificial intelligence and multi-omics data integration, QSAR models will become even more powerful in capturing complex interactions and non-linear relationships between chemical structures and ADMET properties.

In conclusion, In Silico ADMET predictions, empowered by QSAR models, have revolutionized the drug discovery process, expediting lead identification, optimizing lead candidates, and enhancing drug safety profiles. Embracing these computational approaches in drug development not only accelerates the journey from bench to bedside but also opens new possibilities for the discovery of innovative and life-changing therapeutics for the benefit of patients worldwide.

**References**

1. Chandrasekaran, B., Abed, S. N., Al-Attraqchi, O., Kuche, K., & Tekade, R. K. (2018). Computer-aided prediction of pharmacokinetic (ADMET) properties. In *Dosage form design parameters* (pp. 731-755). Academic Press.
2. Cheng, Feixiong, et al. "In silico ADMET prediction: recent advances, current challenges and future trends." *Current topics in medicinal chemistry* 13.11 (2013): 1273-1289.
3. Dudek, Arkadiusz Z., Tomasz Arodz, and Jorge Gálvez. "Computational methods in developing quantitative structure-activity relationships (QSAR): a review." *Combinatorial chemistry & high throughput screening* 9.3 (2006): 213-228.
4. Ferreira, Leonardo LG, and Adriano D. Andricopulo. "ADMET modeling approaches in drug discovery." *Drug discovery today* 24.5 (2019): 1157-1165.
5. Kar, Supratik, and Jerzy Leszczynski. "Recent advances of computational modeling for predicting drug metabolism: a perspective." *Current Drug Metabolism* 18.12 (2017): 1106-1122.
6. Kesharwani, Rajesh Kumar, et al. "Role of ADMET tools in current scenario: application and limitations." *Computer-Aided Drug Design* (2020): 71-87.
7. Kim, Rosa S., Nicolas Goossens, and Yujin Hoshida. "Use of big data in drug development for precision medicine." *Expert review of precision medicine and drug development* 1.3 (2016): 245-253.
8. Lambrinidis, George, and Anna Tsantili-Kakoulidou. "Challenges with multi-objective QSAR in drug discovery." *Expert opinion on drug discovery* 13.9 (2018): 851-859.
9. Muhammad, Umma, Adamu Uzairu, and D. Ebuka Arthur. "Review on: quantitative structure activity relationship (QSAR) modeling." *J Anal Pharm Res* 7.2 (2018): 240-242.
10. Norinder, Ulf, and Christel AS Bergström. "Prediction of ADMET properties." *ChemMedChem: Chemistry Enabling Drug Discovery* 1.9 (2006): 920-937.
11. Oprea, Tudor I., and Hans Matter. "Integrating virtual screening in lead discovery." *Current opinion in chemical biology* 8.4 (2004): 349-358. Oprea, Tudor I., and Hans Matter. "Integrating virtual screening in lead discovery." *Current opinion in chemical biology* 8.4 (2004): 349-358.
12. Pantaleão, Simone Q., et al. "Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review." *ChemMedChem* 17.1 (2022): e202100542.
13. Patel, Harun M., et al. "Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery." *Medicinal chemistry research* 23 (2014): 4991-5007.
14. Wang, Yulan, et al. "In silico ADME/T modelling for rational drug design." *Quarterly reviews of biophysics* 48.4 (2015): 488-515.